Introduction {#Sec1}
============

The registration committee of the Japanese Gastric Cancer Association (JGCA) started a new registration program in 2008 after a 10-year blank period, and we reported the 5-year follow-up data of the patients treated in 2001 \[[@CR1]\]. The registration has been continuing, and here we report the results of those treated in 2002.

Materials and methods {#Sec2}
=====================

Leading hospitals in Japan voluntarily downloaded and fulfilled the database provided by the JGCA and sent the anonymized data to the JGCA data center. The collected data were analyzed according to the previously reported methods \[[@CR1]\].

Results {#Sec3}
=======

Data of 14,394 patients were collected from 208 hospitals; 126 (60.6 %) hospitals participated in both years, but 82 hospitals were new, which was a 10 % increase as compared to the previous year (13,067 patients from 187 hospitals). The geographic distribution of the registered patients among the 47 prefectures is illustrated in Fig. [1](#Fig1){ref-type="fig"}. In Tokyo, 2,332 patients per year were registered, followed by 1,464 in Osaka. Four other prefectures registered more than 500 patients. On the other hand, the number of registered patients was fewer than 100 in 10 prefectures, and there were no registered patients in 2 prefectures.Fig. 1Geographic distribution of registered patients by prefecture

Patients with remnant stomach cancer, non-epithelial malignant tumor, and gastric cancer combined with malignant tumor of other organs were excluded. Patients who were treated by endoscopic mucosal resection were also excluded. Data of 768 patients lacked essential items. Consequently, data of the remaining 13,002 patients were used for the final analysis.

The results are shown in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"}, [9](#Tab9){ref-type="table"}, [10](#Tab10){ref-type="table"}, [11](#Tab11){ref-type="table"}, [12](#Tab12){ref-type="table"}, [13](#Tab13){ref-type="table"}, [14](#Tab14){ref-type="table"}, [15](#Tab15){ref-type="table"}, [16](#Tab16){ref-type="table"}, [17](#Tab17){ref-type="table"}, [18](#Tab18){ref-type="table"}, [19](#Tab19){ref-type="table"}, [20](#Tab20){ref-type="table"}, [21](#Tab21){ref-type="table"}, [22](#Tab22){ref-type="table"}, [23](#Tab23){ref-type="table"}, [24](#Tab24){ref-type="table"}, [25](#Tab25){ref-type="table"}, [26](#Tab26){ref-type="table"}, [27](#Tab27){ref-type="table"}, and [28](#Tab28){ref-type="table"}. Data given for each category of patients are: total number of patients, survival rates by year, standard error of 5YEARS, the number of direct death within 30 postoperative days, the number of patients lost to follow-up within 5 years, the number of 5-year survivors, and main cause of death, such as local and/or lymph node metastasis, peritoneal metastasis, liver metastasis, distant metastasis, recurrence at unknown site, other cancer, and other disease. Figures [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, [6](#Fig6){ref-type="fig"}, [7](#Fig7){ref-type="fig"}, [8](#Fig8){ref-type="fig"}, [9](#Fig9){ref-type="fig"}, [10](#Fig10){ref-type="fig"}, [11](#Fig11){ref-type="fig"}, [12](#Fig12){ref-type="fig"}, [13](#Fig13){ref-type="fig"}, [14](#Fig14){ref-type="fig"}, [15](#Fig15){ref-type="fig"}, [16](#Fig16){ref-type="fig"}, and [17](#Fig18){ref-type="fig"} provide cumulative survival curves of patients stratified by essential categories.Table 1Primary cancerCategoriesNo. of patientsDirect deathLost f.u.1 years (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownPrimary cancer1362689223388.179.674.571.268.90.474364541483388243322167567333*lost f.u.* lost to follow-up, *years(%)* years of cumulative survival rate, *SE* standard error, *rec* recurrence, *peritoneal* peritoneal recurrence, *R* recurrence of unknown siteTable 2Resected cases and unresected cases and other surgeriesCategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownResected cases1300263217389.881.676.573.170.70.472864101283357215278158539303Unresected cases355212525.77.32.91.91.50.743718324243221212Table 3Sex (resected cases)CategoriesNo. of\
patientsDirect deathLost f.u.1 years (%)2 years\
(%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownMale888743146489.781.476.172.570.00.54939292805280136203133425210Female41152070990.182.277.474.372.30.723471184787779752511493Table 4Age (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknown\<3929705093.083.282.180.279.42.419053614401640--5936221058193.486.783.280.378.80.723167832767616428425860--79807540127989.180.574.871.468.90.54450282798255142180110387192\>8010081326381.671.663.957.051.41.833045122348302010947Table 5Tumor location (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownU26811843487.377.571.167.164.31.013561042679976683915088M5182888193.688.484.481.779.70.63322102339101627248153102L42492876690.381.876.873.270.80.7233815938012446905920087Whole58486263.737.928.722.919.31.7883725620244552225*U* upper third, *M* middle third, *L* lower thirdTable 6Macroscopic type (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownType0686913129498.196.194.092.190.20.44959406931222410524481Type136306289.178.671.168.265.52.61871222249952013Type217172129187.075.868.163.060.41.27988614711849612010542Type325751736479.663.354.349.146.01.09141815321587910222115108Type492398663.737.928.221.517.71.31275545012397223644Type533924383.974.567.063.760.62.81711651912831313Table 7Histological type (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 years (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownPapillary adenocarcinoma (pap)46468688.278.870.766.764.32.4227153036713102614tub 12846954296.292.488.385.983.60.7187732714714295114637tub 234581858591.082.877.073.370.80.8193612025913164634816983por 117461030185.075.170.166.364.41.286781192724163136947por 224491530983.070.264.259.657.01.01148120530436380168159Signet-ring cell carcinoma (sig)1581527994.289.085.883.681.51.010301812741718163042Mucinous adenocarcinoma (muc)25903483.768.661.959.355.23.2116145345621114Adenosquamous carcinoma170052.929.423.523.523.510.3421410113Squamous cell carcinoma600100.066.750.050.050.020.4300201000Miscellaneous carcinoma7501877.969.064.262.458.86.129461111023*tub 1* tubular adenocarcinoma, well-differentiated type; *tub 2* tubular adenocarcinoma, moderately differentiated type; *por 1* poorly differentiated adenocarcinoma, solid type, *por 2*, poorly differentiated adenocarcinoma, non-solid typeTable 8Histological findings (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownDifferentiated type676833121393.086.681.378.175.70.5404016736021485105109341134Undifferentiated type60353092386.576.571.567.865.50.6316123390212312616747191162Other type9801874.961.555.754.451.85.336671722136Table 9Lymphatic invasion(ly) (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownly0574410108997.895.393.391.389.60.44108221082121238020270ly131561652492.684.979.775.472.70.81833672788842583814880ly222081432183.269.159.854.951.31.189113537014274872510360ly317692321767.146.136.431.228.61.138718351610577103127891Table 10Venous invasion(v) (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 years (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownv0802722145695.891.688.385.883.40.45344105384685769107308129v128002140585.172.965.160.357.61.0128414644611081843212191v213471118375.557.848.342.940.81.4425100291974475136851v3676910466.145.538.233.331.51.91515414580314433430Table 11Depth of invasion (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownpT1(M)3293968998.897.896.494.993.50.52410373244010926pT1(SM)3110655098.095.893.591.789.70.622681712171395112944pT2(MP)1341425295.891.587.284.882.11.18692531271613176229pT2(SS)21151430687.876.067.962.559.11.199611023612873692910464pT3(SE)25672630172.551.040.333.630.31.06141928391539413814109113pT4(SI)45845257.734.626.321.920.62.0684715428174242125Table 12pT classification (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownpT1640315123998.496.995.093.391.70.4467820192015139123870pT234561855890.982.075.371.167.90.8186513526715589824616693pT325672630172.551.040.333.630.31.06141928391539413814109113pT445845257.734.626.321.920.62.0684715428174242125Table 13Lymph node metastasis (resected cases)categoriesNo. of patientsDirect deathLost f.u.1 yearr (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownpN0760320148297.695.392.990.988.90.453502913252213410730393pN126191737486.373.966.661.458.91.0124011540212459812812472pN220321524676.456.044.538.134.61.154717254213288114157997pN352294154.930.120.316.514.31.6618615836434132231Table 14Peritoneal cytology (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver recDistant meta.*R*Other cancerOther diseaseUnknownCY050751676189.980.073.268.665.60.7267522957620011711260199146CY1761167152.226.118.315.012.31.3724538628365223336Table 15Peritoneal metastasis (P) (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year(%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownfP01200447208292.385.280.377.074.50.47087349862308184218154503257fP1762156248.923.313.99.98.31.1494840244285643138Table 16Liver metastasis (H) (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownfH01244157211491.083.178.074.672.20.471143861197229200247156517281fH132663439.822.315.512.711.41.9231063122122801717Table 17Distant metastasis including peritoneal and liver metastasis (M) (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver recDistant meta.*R*Other cancerOther diseaseUnknownfM01253056212890.482.577.574.171.70.471043761186322185262155518294fM121661553.229.518.113.512.42.42221732826151114Table 18Japanese stage (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownStageIA564014111398.597.195.493.892.20.441261111104118621553StageIB1822536497.294.490.888.185.30.912161441251512277929StageII1424322095.086.580.275.572.11.283450100433030156933StageIIIA1178615988.674.063.156.152.81.550181199553040145643StageIIIB67848582.158.043.834.931.01.91616120538313153229StageIV19023018055.631.021.717.414.90.921818070818010114988098Table 19Japanese stage (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownStageI746219147798.296.494.392.490.50.45342255235192311329482StageII1424322095.086.580.275.572.11.283450100433030156933StageIII18561024486.268.256.148.444.91.2662142404936171198872StageIV19023018055.631.021.717.414.90.921818070818010114988098Table 20TNM stage (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownStage IA556415111198.297.195.593.992.30.4406210994118421054Stage IB1950538597.093.889.987.584.70.912941749251520288433Stage II1614526194.085.478.473.370.01.290362125643534148036Stage IIIA1048913386.168.458.250.646.81.639975204443337155553Stage IIIB47715879.655.641.932.228.82.21074516619182841715Stage IV19242718457.332.822.417.915.20.92231807041891071421283100Table 21TNM stage (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownStageI751420149698.196.294.192.290.30.45356275834193111229487StageII1614526194.085.478.473.370.01.290362125643534148036StageIII15251019184.164.453.244.941.21.3506120370635165197268StageIV19242718457.332.822.417.915.20.92231807041891071421283100Table 22Surgical approach (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownLaparotomy1216659202189.681.276.072.469.90.467453911238346204273147514287Thoracolaparotomy15221370.752.041.438.535.44.045143561053129Laparoscopic658213697.796.495.094.493.31.0481464008136Others60280.060.060.060.060.021.9210000001Table 23Surgical procedures (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownDistal gastrectomy774332140593.186.982.679.977.70.547421975151797212483283143Total gastrectomy39662554881.267.560.154.951.90.8163520775216413814545194138Proximal gastrectomy523211194.891.388.386.585.11.634151292472210Pylorus-preserving gastrectomy39713799.598.295.994.892.61.3332123113143Segmental or local gastrectomy35136795.091.286.282.981.22.22240222417249Surgical mucosal resection2205100.089.578.978.973.310.21200000320Table 24Lymph node dissection (D) (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 ysr (%)2 ysr (%)3 ysr (%)4 ysr (%)5 ysr (%)SE at 5 ysrAliveLocal rec.Peri-tonealLiver rec.Distant meta.*R*Other cancerOther diseaseUn-knownD08021212580.573.769.167.065.61.74201795341017184917D125531545786.479.174.671.268.81.01356582766529564814563D1 + α1684734992.086.183.280.978.61.110083994271331217725D1 + β882216593.588.385.683.581.41.45631845198993313D260562090791.682.276.072.169.60.6342424065418312612453201144D334323582.866.658.451.147.72.813828672117173611Table 25Resection margins (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownPM− and DM−1221756208991.083.178.174.772.30.469843551102332192240155500268PM+ and/or DM+39774350.932.223.418.416.22.0503414418153422730Table 26Combined resection of neighboring organs (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownNo combined resection795533149492.085.681.478.676.50.547291935881618013298326154Combined resection43092961585.173.266.361.558.70.8203219165118312313555192132*PM* proximal margin, *DM* distal marginTable 27Combined resected organs (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownCaudal pancreas31313574.254.545.539.737.52.996287715172231010Spleen14441018984.768.859.653.749.71.457380288617049156851Transverse colon10111971.652.343.038.036.75.225527429073Transverse mesocolon531782.961.453.240.338.17.015315214051Diaphragma90150.825.40.00.00.00.0000420011Liver9621163.649.240.234.533.25.0247111748266Gallbladder21211233989.181.977.373.571.21.0121559213732240288052Adrenal gland100090.080.080.080.080.012.6810000001Kidney70285.785.785.768.668.618.6300000110Small intestine100190.070.060.060.060.015.5501000021Abdominal wall1000.00.00.00.00.00.0000100000Ovary220367.452.141.741.741.711.07011010000Pancreas head (PD)202285.069.158.441.835.911.3620102151Others660486.475.667.967.967.95.84115321423*PD* pancreatoduodenectomyTable 28Curative potential (resected cases)CategoriesNo. of patientsDirect deathLost f.u.1 year (%)2 years (%)3 years (%)4 years (%)5 years (%)SE at 5 yearsAliveLocal rec.PeritonealLiver rec.Distant meta.*R*Other cancerOther diseaseUnknownA810220158597.895.492.990.688.60.4567458119663939113300109B30781439888.372.562.156.152.50.913182065081379411539155108C15052814949.024.716.412.19.90.81091266241507812037175Fig. 2Kaplan--Meier survival for all patients with primary gastric cancer. *5YEARS* 5-year survival rateFig. 3Kaplan--Meier survival for resected cases and unresected casesFig. 4Kaplan--Meier survival of resected cases stratified by sexFig. 5Kaplan--Meier survival of resected cases stratified by ageFig. 6Kaplan--Meier survival of resected cases stratified by tumor location. *W* whole stomachFig. 7Kaplan--Meier survival of resected cases stratified by macroscopic typeFig. 8Kaplan--Meier survival of resected cases stratified by histological findingsFig. 9Kaplan--Meier survival of resected cases stratified by lymphatic invasionFig. 10Kaplan--Meier survival of resected cases stratified by depth of tumor invasionFig. 11Kaplan--Meier survival of resected cases stratified by pT classificationFig. 12Kaplan--Meier survival of resected cases stratified by lymph node metastasisFig. 13Kaplan--Meier survival of resected cases stratified by peritoneal cytologyFig. 14Kaplan--Meier survival of resected cases stratified by peritoneal metastasisFig. 15Kaplan--Meier survival of resected cases stratified by Japanese Gastric Cancer Association (JGCA) stageFig. 16Kaplan--Meier survival of resected cases stratified by TNM stage

The 5YEARS in 13,626 patients with primary gastric cancer was 68.9 % (Table [1](#Tab1){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}). During the 5-year follow-up, 2,233 patients were lost; the follow-up rate was 83.6 %. Of the 13,626 patients, 13,002 underwent gastric resection. Accordingly, the resection rate was 95.4 %, and the 5YEARS of the resected patients was 70.7 % (Table [2](#Tab2){ref-type="table"}; Fig. [3](#Fig3){ref-type="fig"}). Sixty-three of 13,002 resected cases died within 30 days postoperatively. The direct death rate was 0.48 %. The frequent causes of death in patients who had undergone gastrectomy were peritoneal metastasis (*n* = 1,283), followed by other diseases (*n* = 539), local recurrence including node metastasis (*n* = 410), liver metastasis (*n* = 357), recurrence at unknown site (*n* = 278), and other cancer (*n* = 158).

The proportion of male patients was 68.4 % with 5YEARS of 70.0 %; for female patients 5YEARS was 72.3 %, which was better statistically (Table [3](#Tab3){ref-type="table"}; Fig. [4](#Fig4){ref-type="fig"}). Patients more than 80 years old were 7.8 % of all patients, and their 5YEARS was 51.4 % (Table [4](#Tab4){ref-type="table"}; Fig. [5](#Fig5){ref-type="fig"}). On the other hand, 5YEARS of the patients under 39 years old was 79.4 % (*P* \< 0.001). Cancer was located in the upper-third of the stomach in 21.1 % of the cases, and its 5YEARS was relatively low at 64.3 % (Table [5](#Tab5){ref-type="table"}; Fig. [6](#Fig6){ref-type="fig"}). Patients with type 4 cancer amounted to 7.2 %, and their 5YEARS was markedly low at 17.7 % (Table [6](#Tab6){ref-type="table"}; Fig. [7](#Fig7){ref-type="fig"}). The 5YEARS of type 3 was 46.0 % and that of type 2 was 60.4 %. For histological type, frequency of the undifferentiated type including poorly differentiated adenocarcinoma, signet-ring cell carcinoma, and mucinous adenocarcinoma was 46.8 % and its 5YEARS was 65.5 %, which was inferior to that of the differentiated type (75.7 %, *P* \< 0.001; Tables [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"}; Fig. [8](#Fig8){ref-type="fig"}). The grade of lymphatic invasion (ly0--ly3) and venous invasion (v0--v3) showed significant correlations with the prognosis (Tables [9](#Tab9){ref-type="table"}, [10](#Tab10){ref-type="table"}; Fig. [9](#Fig9){ref-type="fig"}).

A high incidence of early-stage cancer remained characteristic in 2002, as shown in Tables [11](#Tab11){ref-type="table"} and [12](#Tab12){ref-type="table"}. The proportion of pathological M and SM (pT1) cancer was 49.7 %, and its primary cause of death was not cancer recurrence (17.9 %, *n* = 87) or other cancer (18.7 %), but other diseases (49.0 %, *n* = 238). The proportion of pathological MP and SS (pT2) was 26.8 %, SE (pT3) 19.9 %, and SI (pT4) 3.6 %. The 5YEARS of these subsets were 67.9 %, 30.3 %, and 20.6 %, respectively (Figs. [10](#Fig10){ref-type="fig"}, [11](#Fig11){ref-type="fig"}). The primary cause of death in advanced cancer was cancer recurrence, and the peritoneal recurrence rate was remarkably high in the pT3 and pT4 subsets. For the lymph node metastasis, the proportion of pN0 was 59.5 %, pN1 20.4 %, pN2 15.9 %, and pN3 4.1 %, and the 5YEARS of each subset was 88.9 %, 58.9 %, 34.6 %, and 14.3 %, respectively (Table [13](#Tab13){ref-type="table"}; Fig. [12](#Fig12){ref-type="fig"}).

Peritoneal washing cytology was carried out in 5,836 patients with advanced gastric cancer; the positive rate was 13.0 %. The 5YEARS of cytology-positive (CY1) patients was 12.3 %, which was almost as dismal as the 5YEARS of the P1 patients (8.3 %; Tables [14](#Tab14){ref-type="table"}, [15](#Tab15){ref-type="table"}; Figs. [13](#Fig13){ref-type="fig"}, [14](#Fig14){ref-type="fig"}). The 5YEARS of patients with liver metastasis (H1) was 11.4 %, and of those with other types of distant metastasis was 12.4 % (Tables [16](#Tab16){ref-type="table"}, [17](#Tab17){ref-type="table"}).

The 5YEARS of the patients stratified by JGCA staging system was 92.2 % for stage IA, 85.3 % for stage IB, 72.1 % for stage II, 52.8 % for stage IIIA, 31.0 % for stage IIIB, and 14.9 % for stage IV. These JGCA 5YEARSs seemed to correlate well with TNM 5YEARSs, which were 92.3 % for stage IA, 84.7 % for stage IB, 70.0 % for stage II, 46.8 % for stage IIIA, 28.8 % for stage IIIB, and 15.2 % for stage IV (Table [18](#Tab18){ref-type="table"}, [19](#Tab19){ref-type="table"}, [20](#Tab20){ref-type="table"}, [21](#Tab21){ref-type="table"}; Figs. [15](#Fig15){ref-type="fig"}, [16](#Fig16){ref-type="fig"}).

For operative procedures, the proportion of patients who underwent laparoscopic gastrectomy was only 5.1 % in 2002, and their 5YEARS was 93.3 % (Table [22](#Tab22){ref-type="table"}). Eligibility for laparoscopic surgery was strictly limited at that time, and the laparoscopic approach was selected almost exclusively in patients with the preoperative diagnosis of early gastric cancer. Only 1.2 % of the patients were treated by thoracolaparotomy, and their 5YEARS was 35.4 %. Thoracolaparotomy was usually carried out in patients with advanced gastric cancer with esophageal invasion more than 3 cm in length. Total gastrectomy was performed for 30.5 % of the patients, and their 5YEARS was 51.9 % (Table [23](#Tab23){ref-type="table"}). D2 lymph node dissection, a standard procedure for resectable advanced gastric cancer according to the JGCA treatment guidelines, was performed in 49.2 % of the patients (Table [24](#Tab24){ref-type="table"}) \[[@CR2], [@CR3]\]. The risk of direct death among those who underwent D2 gastrectomy was only 0.3 %. The proportion of patients treated with less invasive surgery such as proximal gastrectomy, pylorus-preserving gastrectomy, segmental gastrectomy, and local resection of the stomach was 9.8 %. D0, D1, D1 + α, and D1 + β dissection were carried out in 6.5 %, 20.7 %, 13.7 %, and 7.2 % of the patients, respectively. D0 and D1 dissection were carried out mainly in patients with noncurative factors or poor surgical risks. The incidence of positive resection margin (PM+ and/or DM+) was 3.1 % (Table [25](#Tab25){ref-type="table"}). Combined resection of other organs was performed in 35.1 % (Table [26](#Tab26){ref-type="table"}). The frequent combined resected organs in patients who underwent gastrectomy were gallbladder (*n* = 2121), spleen (*n* = 1444), caudal pancreas (*n* = 313), transverse colon (*n* = 101), liver (*n* = 96), and so on in descending order (Table [27](#Tab27){ref-type="table"}).

The curative potential of gastric resection was an important prognostic factor. The proportion of patients with no residual tumors with high probability of cure (resection A) was 63.9 %, and their 5YEARS was 88.6 %. On the other hand, patients with definite residual tumors (resection C) amounted to 11.9 % of all patients who underwent laparotomy, and their 5YEARS was 9.9 % (Table [28](#Tab28){ref-type="table"}; Fig. [17](#Fig17){ref-type="fig"}).Fig. 17Kaplan--Meier survival of resected cases stratified by curative potential of gastric resection

Discussion {#Sec4}
==========

Estimates of the worldwide incidence, mortality, and prevalence of 26 cancers in the year 2002 were available in the GLOBOCAN series of the International Agency for Research on Cancer \[[@CR4]\]. With an estimated 934,000 new cases per year in 2002 (8.6 % of new cancer cases), the incidence of stomach cancer is in fourth place, after cancers of the lung, breast, and colon and rectum. It is the second most common cause of death from cancer (700,000 deaths annually).

The data presented in this report were collected from 208 hospitals in Japan. Cancer incidence rate (annual number of newly diagnosed cases per 100,000 population) in Japan in 2002 was approximately 520 for males and 370 for females. The incidences of various cancers in Japan are estimated from data collected by the cancer registry system in a dozen prefectures. According to these statistics, the number of cancer incidences in 2002 was approximately 589,000. The stomach was the leading site (21 %) for males and the second highest site (14 %) for females. The number of new patients who were diagnosed as gastric cancer in 2002 was estimated to be 106,760 \[[@CR5]\]. Accordingly, 13,626 patients registered by this program corresponded to approximately 13 % of the whole population affected by gastric cancer in Japan. Even though these patients may not represent the average features of gastric cancer found in this country, this report is considered to have analyzed the largest number of patients for the past 10 years, clarifying the trends of gastric cancer in Japan. Just for reference, the proportion of patients registered in the nationwide registry of other organs of all patients diagnosed were 6 % in colon cancer, 24 % in esophageal cancer, 25 % in liver cancer, and 26 % in lung cancer, respectively \[[@CR6]\].

The reliability of the results in this report depends on the quality of data accumulated in the JGCA database. Because of the complexity of the JGCA staging system, the error checking system on the data entry screen did not function completely. In several categories such as lymph node metastasis (N), the JGCA system could not be converted to the TNM system automatically. Therefore, the registration committee had to make great efforts to confirm raw data sent to the data center from the participating hospitals.

As compared with our archived data of 12,004 patients treated in 2001 \[[@CR1]\], the proportion of early cancer declined from 51.2 % to 49.7 % \[pT1 (M) cancer, 27.4 % to 25.6 %, and pT1 (SM) cancer, 23.8 % to 24.1 %\], suggesting that an increasing number of patients with mucosal cancer were sent for endoscopic treatment. These data suggest that we should start to register gastric patients treated with endoscopic mucosal resection (EMR) and/or endoscopic submucosal dissection (ESD) as soon as possible. The surgical mortality within 30 days significantly improved, from 0.6 % to 0.48 % (*P* \< 0.001). Just for reference, it was 4.0 % in 1963 and 1.0 % in 1991 \[[@CR7]\], Moreover, the nationwide database of gastrointestinal surgery in 2008 showed that was 0.2 % in gastrectomy and 0.4 % in total gastrectomy \[[@CR8]\].

Accordingly with the rapidly aging society in Japan, the proportion of patients more than 80 years old continued increasing (Fig. [18](#Fig18){ref-type="fig"}): it was 0.7 % in 1963, 4.9 % in 1990, 7.0 % in 2001, and 7.8 % in 2002, respectively. Although the risk for surgery increases in elderly patients who have comorbidities, evaluations of risk can allow interventions that may decrease morbidity and mortality. Appropriate treatments should be offered to the elderly. However, these data have the intrinsic weakness of being retrospectively collected 7 years after surgery. Unfortunately, we in Japan continue to have a legal difficulty in registering personal information, which is essential for long-term and prospective follow-up. The overall follow-up rate in our program was 83.5 %. In other words, the outcome of 17.5 % of the patients is unknown. The proportion of patients who were lost to follow-up in the Japanese nationwide registry of colon cancer, liver cancer, and thyroid cancer was 19.6 %, 25.8 %, and 20.6 %, respectively \[[@CR6]\]. Rules and regulations regarding handling of these data will have to change radically to overcome the issue of accuracy and reliability of the nationwide registry in Japan, and this could be out of the hands of the surgeons who have contributed to the best of their abilities to gather these data. On the other hand, the Japanese Association of Clinical Cancer Centers, consisting of 25 cancer center hospitals, reported that their follow-up rate was 98.5 %, and 5YEARS of 9,980 patients who underwent surgery from 1997 to 2000 were 90.4 % for TNM stage I, 67.8 % for stage II, 43.3 % for stage III, and 9.3 % for stage IV, respectively \[[@CR9]\]. When the patients with gastric cancer had a medical examination in clinical cancer centers, they registered the place where their family records were registered, and office workers of the clinical cancer centers confirmed regularly their safety from the family registration; this was the reason for the extremely high follow-up rate. In the current analyses, 5YEARS in stage IV patients was 15.2 %. We might have overestimated our 5YEARS in stage IV patients, but we found that our follow-up rate increased as the stage advanced; the follow-up rate of stage IV patients was 90.4 %. These data suggest that the lower follow-up rate may not have had serious effects on 5YEARSs in our program. Although, the correlation between follow-up rate and survival rate is complicated, our follow-up system needs to be improved if we are to evaluate the survival rates more accurately.Fig. 18Chronological change of gastric cancer patients older than 80 years. The nationwide registry was suspended for a decade from 1992

Cytological examination was conducted in 3,481 (59.4 %) of 5,857 patients with T2, T3, or T4 cancer. The 5YEARS of CY1 patients was 12.3 % and their 5YEARS was as poor as that of patients with peritoneal metastasis. Although this examination was not carried out commonly in the days of 2002, it could still be regarded as a significant and independent prognostic factor from the data that were available. These findings further support the need for staging laparoscopy for accurate preoperative staging in patients with advanced gastric cancer.

JGCA restarted a nationwide registration from 2008. The object of the new nationwide registry was primarily to calculate the stage-specific 5YEARSs among patients who underwent gastrectomy. Therefore, the structure of the database was required to be simple, and the number of registration items was kept to a minimum. Undoubtedly, the next objective would be to collect and analyze data of patients with inoperable disease, remnant gastric cancer, gastrointestinal stromal tumor, malignant lymphoma of the stomach, and other entities that were excluded in the current project. We also began to register patients who were treated by EMR/ESD by adding additional items and updating data entry software from 2011.

We hope that this report will be useful when surveying trends and changes in the clinical practice and treatment results of gastric cancer in Japan. Details of the individual data presented in this report will soon become available for scientific and clinical research with the permission of the registration committee. In addition, most of the surgical and pathological data could easily be transferred to the international database in the near future for various analyses. The registration committee will continue the efforts to improve the registration system, ultimately to collect meaningful annual data.

The JGCA Registration Committee appreciates the great effort of participating hospitals in registering accurate and detailed data for this project. I wish to express my great gratitude to Ms. Yoshimi Sugamura, Niigata University Medical and Dental Hospital, for her valuable assistance.
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Appendix: Participating hospitals {#Sec5}
=================================

Data of gastric cancer patients in this report were collected from the surgical or gastrointestinal departments of the following 208 hospitals (in alphabetical order): Akashi Municipal Hospital, Aomori City Hospital, Asahikawa Medical University Hospital, Cancer Institute Hospital, Chiba Cancer Center, Chiba University Hospital, Dokkyo Medical University Hospital, Ebina General Hospital, Fuchu Hospital, Fujita Health University (Banbuntane Houtokukai Hospital), Fukaya Red Cross Hospital, Fukui Red Cross Hospital, Fukuoka University Chikushi Hospital, Fukuoka University Hospital, Fukushima Medical University Hospital, Gifu Prefectural General Medical Center, Gifu University Hospital, Gunma Prefectural Cancer Center, Gunma University Hospital, Hakodate Goryoukaku Hospital, Hakodate Municipal Hospital, Hamamatsu University School of Medicine, University Hospital, Handa City Hospital, Health Insurance Hitoyoshi General Hospital, Higashiosaka City General Hospital, Himeji Central Hospital, Hiroshima City Asa Hospital, Hiroshima City Hospital, Hiroshima Prefectural Hospital, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima University Hospital, Hitachi General Hospital, Hokkaido University Hospital, Hoshigaoka Koseinenkin Hospital, Hospital, University of the Ryukyus, Hyogo Cancer Center, Hyogo Prefectural Nishinomiya Hospital, Ibaraki Prefectural Central Hospital, Ibaraki Seinan Medical Center Hospital, Ishikawa Prefectural Central Hospital, Iwate Medical University Hospital, Iwate Prefectural Central Hospital, Iwate Prefectural Kamaishi Hospital, Izumi Municipal Hospital, JA Hiroshima Kouseiren Hiroshima General Hospital, Japanese Red Cross Medical Center, Jikei University School of Medicine, Jikei University Aoto Hospital, Juntendo University Juntendo Hospital, Jusendo Medical Hospital, Kagawa Prefectural Central Hospital, Kagawa Medical University Hospital, Kakogawa Municipal Hospital, Kanagawa Cancer Center, Kanazawa University Hospital, Kansai Electric Power Hospital, Kansai Rousai Hospital, Kawasaki Medical School Hospital, Keio University Hospital, Keiyukai Sapporo Hospital, Kimitsu Chuo Hospital, Kinki Central Hospital, Kinki University Hospital, Kiryu Kosei General Hospital, Kitakyushu Municipal Medical Center, Kobe Century Memorial Hospital, Kobe City Medical Center General Hospital, Kouchi Medical School Hospital, Kumamoto Medical Center, Kumamoto Regional Medical Center, Kumamoto University Hospital, Kurashiki Central Hospital, Kurobe Kyosai Hospital, Kuroishi General Hospital, Kurume University Hospital, Kushiro Rosai Hospital, Kyorin University Hospital, Kyoto Second Red Cross Hospital, Kyoto University Hospital, Kyushu University Hospital, Matsushita Memorial Hospital, Matsuyama Red Cross Hospital, Misawa City Hospital, Mitoyo General Hospital, Miyagi Cancer Center, Mizushima Kyodo Hospital, Muroran City General Hospital, Musashino Red Cross Hospital, Nagahama City Hospital, Nagano Municipal Hospital, Nagano Red Cross Hospital, Nagaoka Chuo General Hospital, Nagasaki Municipal Hospital, Nagoya University Hospital, Nakagami Hospital, Nanpuh Hospital, Nara Medical University Hospital, Nara Hospital, Kinki University Faculty of Medicine, National Cancer Center Hospital, National Defense Medical College Hospital, NHO Ciba Medical Center, NHO Kasumigaura Medical Center, NHO Kyushu Cancer Center, NHO Osaka Medical Center, NHO Sendai Medical Center, NHO Shikoku Cancer Center, NHO Tokyo Medical Center, NHO Yokohama Medical Center, Nihon University Itabashi Hospital, Nihon University Surugadai Hospital, Niigata Cancer Center Hospital, Niigata City General Hospital, Niigata Prefectural Shibata Hospital, Niigata Prefectural Yoshida Hospital, Niigata University Medical and Dental Hospital, Nippon Koukan Hospital, Nippon Medical School Chiba Hokusoh Hospital, Nippon Medical School Hospital, Nishi-kobe Medical Center, NTT West Osaka Hospital, Obihiro Tokushukai Hospital, Oita Red Cross Hospital, Oita University Hospital, Okayama University Hospital, Okitama Public General Hospital, Onomichi Municipal Hospital, Osaka City University Hospital, Osaka General Medical Center, Osaka Kouseinenkin Hospital, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka Medical College Hospital, Osaka Police Hospital, Osaka Red Cross Hospital, Osaka Seamen's Insurance Hospital, Osaka University Hospital, Otsu Municipal Hospital, Otsu Red Cross Hospital, Rinku General Medical Hospital, Sado General Hospital, Saga University Hospital, Saiseikai Chuwa Hospital, Saiseikai Fukuoka General Hospital, Saiseikai Kumamoto Hospital, Saiseikai Niigata Daini Hospital, Saiseikai Noe Hospital, Saiseikai Utsunomiya Hospital, Saitama Medical Center, Saitama Medical Center Jichi Medical University, Saitama Red Cross Hospital, Saitama Social Insurance Hospital, Saku Central Hospital, Sapporo City General Hospital, Sapporo Medical Center, Sapporo Medical University Hospital, Sapporo Social Insurance General Hospital, Sayama Hospital, Seirei Hamamatsu General Hospital, Shakaihoken Kobe Central Hospital, Shiga University of Medical Science Hospital, Shimonoseki City Central Hospital, Shinnittetsu Yahata Memorial Hospital, Shinshu University Hospital, Shizuoka Cancer Center, Showa Inan Hospital, Showa University Northern Yokohama Hospital, Showa University Toyosu Hospital, Social Insurance Central General Hospital, Social Insurance Kinan Hospital, Southern Tohoku General Hospital, St. Luke's International Hospital, St. Marianna University School of Medicine Yokohama City West Hospital, Suita Municipal Hospital, Sumitomo Hospital, Suwa Red Cross Hospital, Takeda General Hospital, Tochigi Cancer Center, Toho University Ohashi Medical Center, Tohoku University Hospital, Tokushima Municipal Hospital, Tokushima Prefectural Central Hospital, Tokushima University Hospital, Tokyo Medical University Ibaraki Medical Center, Tokyo Metropolitan Bokutoh Hospital, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo Women's Medical University (Institute of Gastroenterology), Tokyo Women's Medical University Hospital, Tokyo Women's Medical University Medical Center East, Tonami General Hospital, Toranomon Hospital, Tottori Municipal Hospital, Toyama Prefectural Central Hospital, Toyama University Hospital, Toyohashi Municipal Hospital, Tsuchiura Kyodo General Hospital, Tsukuba University Hospital, University Hospital Kyoto Prefectural University of Medicine, University of Fukui Hospital, University of Miyazaki Hospital, University of Yamanashi Hospital, Wakayama Medical University Hospital, Yamachika Memorial General Hospital, Yamagata Prefectural Central Hospital, Yamagata University Hospital, Yamaguchi Rousai Hospital, Yamanashi Prefectural Central Hospital, Yao Municipal Hospital, Yodogawa Christian Hospital, Yokohama City University Hospital, Yokohama City University Medical Center, and Yuri Kumiai General Hospital.
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